Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional ...

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders ...

"Monogenic" diseases, triggered by mutations in just one gene, may actually be more complex than scientists thought.

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

Black patients with inherited retinal diseases who undergo genetic testing are less likely than White patients to receive a conclusive genetic diagnosis, new research shows. At one center, about 39% ...

Retinal diseases are at the forefront of a quiet revolution in the realm of ophthalmology. Gene therapy, once a distant dream, is now emerging as a beacon of hope for millions affected by these ...

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

Please provide your email address to receive an email when new articles are posted on . The loss of UBAP1L gene function appears to be associated with nonsyndromic retinal dystrophy, according to ...

Scientists at the National Institutes of Health (NIH) and their colleagues have identified a gene responsible for some inherited retinal diseases (IRDs), which are a group of disorders that damage the ...

A new study challenges what's long been assumed about genetic variants thought to always cause inherited blindness. Investigators from Mass General Brigham used large public biobanks to determine that ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Gene therapy with voretigene neparvovec-rzyl partially restores geniculostriate pathway function in LCA2 patients, improving visual processing. Initial LCA2 pathology shifts visual processing from the ...